Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider John Fesko sold 6,517 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the transaction, the insider directly owned 197,257 shares of the company’s stock, valued at $63,424,043.21. This represents a 3.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John Fesko also recently made the following trade(s):
- On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The stock was sold at an average price of $267.99, for a total transaction of $79,057.05.
- On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $236,539.17.
- On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18.
Natera Price Performance
NASDAQ:NTRA traded down $12.44 during mid-day trading on Friday, hitting $326.26. 833,644 shares of the company’s stock were exchanged, compared to its average volume of 1,496,455. The company has a market cap of $47.03 billion, a PE ratio of -239.90 and a beta of 1.51. Natera, Inc. has a one year low of $157.43 and a one year high of $343.18. The business has a fifty day moving average price of $285.07 and a 200 day moving average price of $233.61.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of NTRA. California State Teachers Retirement System increased its holdings in Natera by 28,373.5% in the 2nd quarter. California State Teachers Retirement System now owns 56,324,789 shares of the medical research company’s stock worth $15,289,364,000 after buying an additional 56,126,974 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares during the period. BlackRock Inc. purchased a new stake in shares of Natera during the 2nd quarter valued at about $2,962,770,000. Wellington Management Group LLP grew its stake in shares of Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares during the period. Finally, State Street Corp grew its stake in shares of Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after acquiring an additional 72,087 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.
Wall Street Analyst Weigh In
A number of research firms have recently commented on NTRA. Leerink Partners set a $330.00 target price on Natera in a research note on Friday, August 7th. Royal Bank Of Canada upped their price target on shares of Natera from $275.00 to $350.00 and gave the stock an “outperform” rating in a research note on Friday, August 7th. Wolfe Research started coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective on the stock. Canaccord Genuity Group set a $375.00 price objective on shares of Natera in a research note on Friday, August 7th. Finally, TD Cowen lifted their target price on shares of Natera from $325.00 to $340.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $319.38.
Get Our Latest Stock Analysis on NTRA
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
- Five stocks we like better than Natera
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
